Dermelle (also doing business as EternoGen) develops nanometric collagen scaffolds intended for a range of soft-tissue therapeutic and aesthetic uses. Its platform can incorporate various nanoparticles, which the company says enables potential applications in skin regenerative wound healing, cartilage lubrication and regeneration for arthritis, and possibly bone regeneration. The company is targeting commercialization in European and Asian markets and aims to position for a regulatory clinical study in Europe. Leadership named in the SEC filing includes CEO Luis Jimenez and chief commercialization officer Anna Lundvall Tenstam, along with several other officers and directors. Dermelle raised $920,427 to close a Series A and has an SEC filing indicating it is seeking an additional $5,579,573 to fund formal clinical studies, commercial-scale production, and marketing and branding to establish a sustainable, revenue-generating business model. The Series A funds will pay for full-spectrum safety tests and pilot human studies to ready the technology for regulatory trials and market entry. The company plans to pursue a Series B from venture capitalists and potential corporate partners and said it could enter the aesthetic market by the end of 2014.

Total raised

$1M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2013